The FDA last week approved Pfizer’s Ruxience, a biosimilar to Roche’s Rituxan, for the treatment of chronic lymphocytic leukemia, non-Hodgkin lymphoma, microscopic polyangiitis and granulomatosis with polyangiitis. For the treatment of chronic lymphocytic leukemia, Rituxan currently holds preferred status in the pharmacy benefit for just 5% of all covered lives, growing to 18% with prior authorization and/or step therapy.

SOURCE: MMIT Analytics, as of 7/26/19